SCHEMBL63126

SCHEMBL63126

OCc1ccc(CO)c(CO)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.47
KDM4E B2RXH2 1/20 0.43
CASP6 P55212 1/20 0.43
CA12 O43570 1/20 0.41
CA2 P00918 1/20 0.41
CA3 P07451 1/20 0.41
CA4 P22748 1/20 0.41
CA6 P23280 1/20 0.41
CA5A P35218 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41
CA5B Q9Y2D0 1/20 0.41
TSHR P16473 1/20 0.39
RECQL P46063 1/20 0.38
ENPP2 Q13822 1/20 0.38
MAPT P10636 1/20 0.38
ACHE P22303 1/20 0.38
SHBG P04278 1/20 0.37
TTR P02766 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29366879 1.00 EGFR (0.47) EGFRKDM4ECASP6CA12CA2
SCHEMBL22490117 0.85 EGFR (0.46) EGFRKDM4ECASP6CA12CA2
SCHEMBL4928195 0.85 EGFR (0.42) EGFRKDM4ECASP6CA12CA2
SCHEMBL5871273 0.82 KDM4E (0.52) EGFRKDM4ECASP6CA12CA2
SCHEMBL8770880 0.82 TRPA1 (0.48) EGFRMAPTSHBGVDRPDE4A
SCHEMBL2601933 0.82 CA1 (0.35) EGFRKDM4ECASP6CA2TSHR
SCHEMBL148755 0.79 SHBG (0.48) EGFRKDM4ECASP6TSHRRECQL
SCHEMBL29741490 0.79 SHBG (0.48) EGFRKDM4ECASP6TSHRRECQL
SCHEMBL11786007 0.79 TTR (0.47) EGFRKDM4ECASP6CA2CA4
SCHEMBL29942487 0.79 PKM (0.55) EGFRKDM4ECASP6CA2CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112209842-A Polyamine synthesis method and polyamine 深圳飞扬骏研新材料股份有限公司 2021-01-12 CN claimed
EP-1747213-B1 NOVEL 7,7-DISUBSTITUTED DERIVATIVES OF (5H,9H)-6,8-DIOXABENZOCYCLOHEPTENE, PREPARATION METHOD THEREOF AND USE OF SAME IN THE SYNTHESIS OF NON-STEROIDAL VITAMIN D ANALOGUES GALDERMA RES & DEV (FR) 2010-05-26 EP claimed
CN-100379779-C Non-heating curable adhesive and method for producing molded body using same E TEC CO LTD (JP) 2008-04-09 CN claimed
US-7319155-B2 7,7-disubstituted (5H,9H)-6,8-dioxabenzocycloheptene compounds useful in the synthesis of non-steroidal analogues of vitamin D GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-01-15 US claimed
US-20070117989-A1 Methanesulfonic acid [7-(4-nitrophenyl)-(5H,9H)-6,8-dioxabenzocyclohepten-2-yl]methyl ester; chemical intermediates GALDERMA RESEARCH & DEVELOPMENT (FR) 2007-05-24 US claimed
EP-1747213-A1 NOVEL 7,7-DISUBSTITUTED DERIVATIVES OF (5H,9H)-6,8-DIOXABENZOCYCLOHEPTENE, PREPARATION METHOD THEREOF AND USE OF SAME IN THE SYNTHESIS OF NON-STEROIDAL VITAMIN D ANALOGUES Galderma Research & Development, S.N.C. (FR) 2007-01-31 EP claimed
US-20060119018-A1 Cold-curing binder and process ror producing molding with the same E-TEC CO., LTD. (JP) 2006-06-08 US claimed
WO-2005116007-A1 NOVEL 7,7-DISUBSTITUTED DERIVATIVES OF (5H,9H)-6,8-DIOXABENZOCYCLOHEPTENE, PREPARATION METHOD THEREOF AND USE OF SAME IN THE SYNTHESIS OF NON-STEROIDAL VITAMIN D ANALOGUES GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-12-08 WO claimed
CN-1703436-A Non-heating curable adhesive and method for producing molded body using same E TEC CO LTD (JP) 2005-11-30 CN claimed
EP-1559732-A1 COLD-CURING BINDER AND PROCESS FOR PRODUCING MOLDING WITH THE SAME E-Tec Co., Ltd. (JP) 2005-08-03 EP claimed
CN-114790131-A Positive electrode lithium supplement additive, positive electrode plate, preparation method of positive electrode plate and lithium ion battery 孚能科技(赣州)股份有限公司 2022-07-26 CN disclosed
EP-3130597-B1 OLIGONUCLEOTIDE HAVING A NON-NATURAL NUCLEOTIDE AT THE 5'-TERMINAL KYOWA KIRIN CO LTD (JP) 2021-11-10 EP disclosed
CN-112209842-A Polyamine synthesis method and polyamine 深圳飞扬骏研新材料股份有限公司 2021-01-12 CN disclosed
EP-3229075-B1 PHOTORESIST COMPOSITION, METHOD FOR MANUFACTURING SAME, AND METHOD FOR FORMING RESIST PATTERN JSR CORP (JP) 2021-01-06 EP disclosed
US-10725376-B2 Pattern-forming method JSR CORPORATION (JP) 2020-07-28 US disclosed
US-4906693-A Transesterification cure of thermosetting coatings THE GLIDDEN COMPANY (US) 1990-03-06 US disclosed
EP-0328950-A1 Coating composition THE GLIDDEN COMPANY (US) 1989-08-23 EP disclosed
US-4749728-A HAVING HYDROXY-FUNCTIONAL AND CARBOXYLIC ESTER-FUNCTIONAL RESINS OR COMPONENTS THE GLIDDEN COMPANY (US) 1988-06-07 US disclosed
EP-0263259-A2 Process and catalyst system for the trimerization of acetylene and acetylene compounds HÜLS AKTIENGESELLSCHAFT (DE) 1988-04-13 EP disclosed
EP-0252289-A2 Transesterification catalysts and thermoset coatings THE GLIDDEN COMPANY (US) 1988-01-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117989-A1 Methanesulfonic acid [7-(4-nitrophenyl)-(5H,9H)-6,8-dioxabenzocyclohepten-2-yl]methyl ester; chemical intermediates CYP24A1, CYP2R1, VDR EGFR 2722/4885KDM4E 486/4885CASP6 167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.